The milestone of 300,000 prodisc® total disc replacements (TDR) is supported by extensive published long-term evidence and validated over decades of clinical success, with a reported reoperation rate of less than 1%.1
prodisc® technology leads the US and international TDR markets through exceptional long-term clinical outcomes, continued innovation of cervical and lumbar TDR products, and recent expanded patient indications.2
Most recently, Centinel Spine received FDA premarket approval in October 2025 for two-level use of the prodisc C Vivo and prodisc C SK cervical TDR devices, expanding total disc replacement treatment options.
Centinel Spine’s prodisc is the only TDR solution in the US with two-level indications approved by the FDA for cervical and lumbar use.
WEST CHESTER, Pa., Nov. 13, 2025 /PRNewswire/ — Centinel Spine®, LLC (“the Company”), the leading global medical device company focused exclusively on the treatment of cervical and lumbar spine diseases with the world’s most comprehensive and clinically proven total disc replacement (TDR) technology platform (prodisc®), today announced that more than 300,000 prodisc devices have now been implanted worldwide. This landmark achievement underscores more than three decades of clinical performance, surgeon confidence and continued expansion of total disc replacement solutions. Centinel Spine will highlight prodisc cervical and lumbar technologies at the upcoming 2025 North American Spine Society (NASS) 40th Annual Meeting in Denver, Colorado, November 14-16, 2025.
The prodisc platform remains the only total disc replacement system to offer multiple anatomically tailored implant solutions for the cervical and lumbar spine, allowing Match-The-Disc™ surgeons to adapt to each patient’s unique anatomy and clinical needs. The design and clinical durability of prodisc have been supported by over 540 published, peer-reviewed articles, with long-term evidence demonstrating sustained function and revision rates less than 1%.1
Reaching 300,000 prodisc implants is a historic milestone that demonstrates the long-term clinical success and durability of the device; However, Centinel Spine continues to aggressively innovate and advance the field of total disc replacement. Recent achievements include FDA approval for bi-level indications of the prodisc L Lumbar TDR device; the introduction of Anatomic Endplate™ versions and new instrumentation for the prodiscL system; the launch of the prodisc C Vivo and prodisc C SK Cervical Match-the-Disc systems; and the limited commercial launch of the prodisc C Nova cervical TDR device. Most recently, the company received FDA approval for two-level use of the prodiscC Vivo and prodisc C SK cervical TDR devices. Centinel Spine remains exclusively dedicated to total disc replacement, with extensive and continued innovation planned for the future.
“prodisc has changed the functional outcomes of my own patients over the past two decades. While this milestone of 300,000 implants is significant, we cannot lose sight of how this advanced surgical technology will continue to shape the future treatment of patients with degenerative spinal conditions for many years to come,” said Michael E. Janssen, DO of the Spine and Orthopedic Center in Denver, Colorado.
“A fixed core center of rotation prosthesis, such as prodisc, provides spinal stability and healthy mobility in the hands of experienced surgeons. Keeping movement controlled reduces mechanical complications and prolongs the longevity of the construct. Reaching 300,000 implants worldwide reflects long-term confidence in the total disc replacement procedure,” added Prof. Dennis Hey, MBBS, FRCS (Orth), Senior Consultant Spine Surgeon at the National University Spine Institute, Clinical Director of Surgery orthopedic at National University Hospital, Chief of Orthopedic and Spine Surgery and Founding Director of the Minimally Invasive and Motion Preserving Spine Unit (MMSU) at Alexandra Hospital, Singapore.
As surgeon adoption expands globally and clinical data continues to mature, Centinel Spine remains committed to advancing total disc replacement for patients worldwide.
“Reaching 300,000 prodisc implants is a significant milestone that reflects the confidence surgeons place in total disc replacement and the significant impact this technology has had on patients,” concluded Steve Murray, CEO of Centinel Spine. “We remain focused on supporting surgeons, providing clinically proven solutions, and promoting total disc replacement as an important treatment option for patients with cervical and lumbar spine diseases.”
1. Based on prodisc complaint handling units in the US since its launch in 2006.
2. Based on publicly available information and data archived as of November 2025.
About Centinel Spine, LLC
Centinel Spine®, LLC is the world’s leading medical device company focused exclusively on addressing cervical and lumbar spine diseases with prodisc®, the world’s most comprehensive total disc replacement (TDR) technology platform.
The company’s prodisc technology is the most studied and clinically tested TDR system in the world, validated by more than 540 published articles and more than 300,000 implants. Centinel Spine’s prodisc is the only TDR technology with multiple motion-preserving anatomical solutions, allowing the surgeon to Match-the-Disc™ with each patient’s anatomy for cervical and lumbar total disc replacement.
For more information, please visit the company’s website at www.CentinelSpine.com or contact:
Varun Gandhi
CFO
900 Airport Road, Suite 3B
West Chester, Pennsylvania 19380
Phone: 484-887-8871
Email: v.gandhi@centinelspine.com
SOURCE Centinel Spine, LLC
